OncoMatch/Clinical Trials/NCT06391034
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
Is NCT06391034 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Non-interventional hormone therapy and hyperpolarized pyruvate +/-urea (13C/15N) for prostate cancer.
Treatment: hyperpolarized pyruvate +/-urea (13C/15N) · Non-interventional hormone therapy — This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Excluded: Stage PELVIC REGIONAL OR DISTANT METASTATIC DISEASE
Evidence of pelvic regional or distant metastatic disease on conventional imaging (MRI, computed tomography or whole body bone scan) or prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET) imaging. PSMA-avid lymph nodes confined to the pelvis will be allowed if <1 centimeter (cm).
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
White Blood Cell count (WBC) >=4000 cells/μL; Hemoglobin ≥9.0 gm/dL; Platelets ≥75,000 cells/μL
Kidney function
Renal Function > 30 Epithelial Growth Factor Receptor (eGFR)
Demonstrates adequate organ function as defined below: White Blood Cell count (WBC) >=4000 cells/μL. Hemoglobin ≥9.0 gm/dL. Platelets ≥75,000 cells/μL. Renal Function > 30 Epithelial Growth Factor Receptor (eGFR).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify